Collegium Pharmaceutical Inc (COLL)

Nov 5, 2026

Collegium Pharmaceutical reported a record quarterly net revenue of $216.3 million in Q3 2026, marking a 3% year-over-year increase, primarily fueled by the strong performance of its ADHD portfolio, including Jornay PM and Azstarys. The ADHD segment now constitutes over 36% of total revenue, with Jornay PM prescriptions growing 16% year-over-year and Azstarys generating $26.5 million in its first full quarter under Collegium's ownership. The company reaffirmed its 2026 financial guidance, emphasizing continued growth in the ADHD business, sustained cash flow from its pain portfolio, and strategic capital allocation including a $50 million accelerated share repurchase program.

Nov 5, 2026

Collegium Pharmaceutical (NASDAQ: COLL) reported Q3 2026 revenue of $216.3 million, meeting Wall Street expectations, and full-year revenue guidance of $840 million, which is slightly above consensus estimates. The company's non-GAAP profit per share exceeded analyst expectations, leading to a 6.7% surge in stock price. Strong demand for its ADHD portfolio, particularly JORNAY PM and AZSTARYS, contributed to these positive results.